Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220512 · ClinicalTrials.gov registry record
The Better, Harder, Faster, Stronger Study
A clinical trial of Ovarian Cancer and Endometrial Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT07220512: Recruiting study of Ovarian Cancer and Endometrial Cancer, sponsored by Wake Forest University Health Sciences.
NCT07220512 is a study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220512, a study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.
Primary Outcome
eFI is an automated electronic medical record-based tool based on a deficit accumulation model of frailty that uses a combination of clinical encounters, diagnosis codes, laboratory workups, and Medicare annual wellness visit data as markers of frailty status.
Conditions Studied
Interventions
- OTHER data collection
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2027-05 |
What NCT07220512 shows while recruiting
NCT07220512 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which data collection is the first listed.
NCT07220512 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07220512 about?
NCT07220512 is a clinical study titled "The Better, Harder, Faster, Stronger Study". The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.
What is the current status of trial NCT07220512?
This trial is currently recruiting. The enrollment target is 35 participants. The study started on 2025-07-28. Estimated completion is 2027-05.
What conditions does trial NCT07220512 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cognitive Dysfunction, Neoadjuvant Chemotherapy, Frailty at Older Adults.
What interventions are being tested in trial NCT07220512?
The interventions under investigation include: data collection (OTHER).
Who is sponsoring clinical trial NCT07220512?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220512 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220512's enrollment target sits among peer trials
35 237th of 322 higher than 81 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI